Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate

REFERENCES

• Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987; 40:1249–55.
   Google Scholar
• Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol. 2006;33:2153–61.
   PubMed Web of Science ®Google Scholar
• Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo con-trolled dose-finding study. J Rheumatol. 2004;31:243–51.
   PubMed Web of Science ®Google Scholar
• Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. 2002;46:2020–8.
   PubMed Web of Science ®Google Scholar
• Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum. 2003;48:3328–37.
   PubMed Web of Science ®Google Scholar
• Morita Y, Sasae Y, Sakuta T, Satoh M, Sasaki T, Kashihara N. Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study. Mod Rheumatol. 2008;18:379–84.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Kameda H, Amano K, Nagasawa H, Takei H, Sekig-uchi N, et al. Single center prospective study of tacrolimus effi-cacy and safety in treatment of rheumatoid arthritis. Rheumatol Int. 2009;29:431–6.
   Google Scholar
• Kitahama M, Okamoto H, Koseki Y, Inoue E, Kaneko H, Taniguchi A, et al. Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis. Mod Rheumatol. 2010;20:478–85.
   PubMed Web of Science ®Google Scholar
• Aramaki T, Kawakami A, Iwamoto N, Fujikawa K, Kawashiri SY, Tamai M, et al. Prediction of DA528-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. Mod Rheumatol. 2009;19:652–6.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum. 2003;48:2763–8.
   Google Scholar
• Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med. 2006;48:135–48.
   Google Scholar
• van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ, et al. Clinical and radiological efficacy of initial vs delayed treatment with inflix-imab plus methotrexate in patients with early rheumatoid arthri-tis. Ann Rheum Dis. 2009;68:1153–8.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol. 2006;16:75–6.
   PubMedGoogle Scholar
• Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Tan-iguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17: 283–9.
   Google Scholar
• Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheuma-toid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 2010;39:360–7.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Inoue E, Mannalithara A, Bennett M, Kamitsuji S, Taniguchi A, et al. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large pro-spective observational cohort study. Mod Rheumatol. 2010;20: 46–53.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the devel-opment of a disease activity score. Ann Rheum Dis. 1990;49: 916–20.
   Google Scholar
• Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
   Google Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Tan-iguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheu-matoid arthritis. Arthritis Rheum. 2003;49: 784–8.
   Google Scholar
• Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the man-agement of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69:964–75.
   Google Scholar
• Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommenda-tions for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009; 68:1086–93.
   Google Scholar